Joe Kiani runs one of the world’s most admired medical technology companies, is an inventor of world-changing noninvasive patient monitoring devices, a trusted voice for patient safety and care, and a convention-breaking maverick. As the founder, Chairman, and CEO of Masimo, a global medical technology innovator, Mr. Kiani has been a beacon for patient safety and innovation in healthcare for more than 25 years. Convinced that the use of adaptive signal processing could solve the problems of motion artifact and noise that plagued pulse oximetry—widely recognized as the 5th vital sign—he founded Masimo in 1989 to improve patient outcome and reduce the cost of care by taking noninvasive monitoring to new sites and applications.
Under his leadership, Masimo has grown from a “garage start up” into a successful publicly traded company (NASDAQ: MASI) employing more than 4,500 people worldwide and providing its technology and clinical-leading Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry technology directly and through leading OEM patient monitoring manufacturers. Today, Masimo is an innovative powerhouse delivering key noninvasive medical breakthroughs, including: rainbow SET Pulse CO-Oximetry™—the first blood constituent monitoring platform to measure multiple blood constituents noninvasively that previously could only be measured invasively and help clinicians improve patient safety and reduce cost of care. Masimo also introduced wearable rainbow SET Radius-7 as well as the bedside rainbow SET Radical-7 and Patient SafetyNet™—the first remote monitoring and wireless clinician notification system shown to help hospitals improve patient safety and clinical outcomes by dramatically decreasing rescue events and costly ICU transfers. Patient SafetyNet is helping hospitals save lives in places like the post-surgical wards where reliable monitoring was not feasible before due to excessive false alarms. With Root’s new open architecture, cockpit and connectivity hub patient monitoring platform, clinical distraction, complexity and cost are expected to decrease and innovation in patient monitoring are expected to accelerate. Mr. Kiani and Masimo have helped to solve the “unsolvable” problems plaguing patient monitoring through significant inventions with more than 600 issued and pending patents worldwide.
Committed to patient safety, Mr. Kiani founded the Patient Safety Movement Foundation in 2012 and the World Patient Safety, Science & Technology Summit. The Patient Safety Movement Foundation (PSMF) has the goal of eliminating preventable deaths by 2020 in the US, and to significantly reduce preventable deaths in hospitals worldwide. Under Mr. Kiani’s leadership, the Patient Safety Movement Foundation has been able to get over 100 companies to make the pledge to share their data with whoever can use it to make patients safer. Patient Safety Movement is expecting the data sharing pledges will help create a new ecosystem of predictive algorithms, tapping into the individual patient data superhighway, to help clinicians save more lives. In addition, over a dozen Actionable Patient Safety Solutions have been created to help hospitals implement processes to avoid human errors becoming fatal to patients. The Patient Safety Movement has convened hundreds of leading clinicians, hospital CEOs, medical technology CEOs, and government officials from around the globe to work together towards the goal of zero preventable deaths by 2020. Today, PSMF has over 3,500 hospitals from around the world that have committed to patient safety. In January 2016, the hospitals that had joined Patient Safety Movement reported 69,519 lives saved annually.
Joe Kiani also leads Cercacor Labs, a spinoff company from Masimo, and serves on the Board of Children’s Hospital of Orange County, Chapman University’s President’s Cabinet, SDSU’s College of Engineering Advisory Board, Clinton Foundation Executive Council, MDMA Board, Masimo Foundation of Ethics, Innovation and Competition in Healthcare, and is an angel investor and sits on some of the Boards of promising start-up companies with unique positive lifesaving and societal consequences.